Certain blood cancer and arthritis patients have a significantly reduced antibody response to double COVID-19 vaccination in the first six months of being treated with a widely used drug, reveals a new study.
Patients with primary and secondary immunodeficiency are at higher risk of mortality following SARS-CoV-2 infection compared with the general population, according to a new study led by the University of Birmingham.